Shopping Cart
Remove All
Your shopping cart is currently empty
YGT-31 is a PPARγ modulator with an IC50 of 1.72 μM and a Ki of 0.62 μM. It diminishes blood glucose levels and enhances insulin sensitivity in a type 2 diabetes model in db/db mice by inhibiting CDK5-mediated phosphorylation of PPARγ-Ser273. Additionally, YGT-31 exhibits anti-steatotic effects in a mouse model of non-alcoholic fatty liver disease (NAFLD).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | YGT-31 is a PPARγ modulator with an IC50 of 1.72 μM and a Ki of 0.62 μM. It diminishes blood glucose levels and enhances insulin sensitivity in a type 2 diabetes model in db/db mice by inhibiting CDK5-mediated phosphorylation of PPARγ-Ser273. Additionally, YGT-31 exhibits anti-steatotic effects in a mouse model of non-alcoholic fatty liver disease (NAFLD). |
| Targets&IC50 | PPARγ:0.62 μM (Ki), PPARγ:1.72 μM |
| Molecular Weight | 469.41 |
| Formula | C25H18F3NO5 |
| Cas No. | 2835447-74-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.